Cystectomy: Clinical Trials

6 trials of Cystectomy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 2 completed, 1 recruiting. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Active not recruiting 3, Completed 2, Recruiting 1

Follow Cystectomy: new trials by email Literature Review of Cystectomy trials Research Report on Cystectomy

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Role of NAC in cT0 Muscle-invasive Bladder Cancer After Maximal TURBt
cisplatin based neoadjuvant chemotherapy, Radical cystectomy alone - Muscle-Invasive Bladder Carcinoma, Chemotherapy Effect
Phase 3Active not recruitingRegina Elena Cancer Institute2362026-08-132026-08-17
Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC
Gemcitabine, Toripalimab, Disitamab Vedotin (RC48) - MIBC
Phase 3RecruitingZhiquan Hu1702026-07-012026-07-09
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Durvalumab, Tremelimumab, Enfortumab Vedotin - Muscle Invasive Bladder Cancer
Phase 3Active not recruitingAstraZeneca7122021-08-052026-06-04
A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer
Nivolumab, Radical cystectomy (RC), Bempegaldesleukin - Bladder Cancer, Bladder Tumor
Phase 3CompletedBristol-Myers Squibb1142020-02-052024-06-27
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin - Urinary Bladder Cancer, Muscle-invasive
Phase 3Active not recruitingMerck Sharp & Dohme LLC5952019-07-242026-06-30
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
Pembrolizumab, Gemcitabine, Cisplatin - Bladder Cancer
Phase 3CompletedMerck Sharp & Dohme LLC9072019-06-132026-10-08

Conditions studied

Urinary Bladder Neoplasms (5)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (1)

Sponsors

Merck Sharp & Dohme LLC (2)  ·  AstraZeneca (1)  ·  Bristol-Myers Squibb (1)  ·  Regina Elena Cancer Institute (1)  ·  Zhiquan Hu (1)

Countries

Italy (5)  ·  Canada (4)  ·  France (4)  ·  Germany (4)  ·  Israel (4)  ·  Mexico (4)  ·  Poland (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  United States (4)  ·  Argentina (3)  ·  Australia (3)  ·  Belgium (3)  ·  Japan (3)  ·  Russia (3)

Top investigators

Giuseppe Simone, MD (1)

Results publications

PMID 34008425, PMID 10470696, PMID 11157016, PMID 12944571, PMID 15273542, PMID 15814643, PMID 16518661, PMID 17116130, PMID 19826360, PMID 21502557, PMID 26579498, PMID 32360052, PMID 33109737, PMID 41193372, PMID 41707170

NIH funding

2018 (3), 2023 (1)